Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 8/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.52 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402532 | 0.92 | OPRM1 (0.61) | OPRK1OPRM1NMUR2NMUR1OPRD1 | |
| SCHEMBL13437225 | 0.90 | OPRM1 (0.59) | OPRK1OPRM1STAT3NMUR2NMUR1 | |
| SCHEMBL13402435 | 0.88 | STAT3 (0.57) | OPRK1OPRM1STAT3NMUR2NMUR1 | |
| SCHEMBL13402433 | 0.86 | STAT3 (0.56) | OPRK1OPRM1STAT3NMUR2NMUR1 | |
| SCHEMBL13402526 | 0.84 | NMUR2 (0.62) | OPRK1OPRM1NMUR2NMUR1OPRD1 | |
| SCHEMBL13402515 | 0.84 | OPRM1 (0.56) | OPRK1OPRM1NMUR2NMUR1MMP1 | |
| SCHEMBL13402527 | 0.84 | OPRM1 (0.54) | OPRK1OPRM1NMUR2NMUR1MMP1 | |
| SCHEMBL13402497 | 0.84 | OPRM1 (0.65) | OPRK1OPRM1NMUR2NMUR1 | |
| SCHEMBL13402662 | 0.82 | NMUR2 (0.55) | OPRK1OPRM1NMUR2NMUR1PLG | |
| SCHEMBL20174018 | 0.80 | OPRK1 (0.59) | OPRK1OPRM1NMUR2NMUR1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087466-A1 | NOVEL SMALL MOLECULE DNAK INHIBITORS | CHAPERONE TECHNOLOGIES, INC. | 2010-04-08 | — | — | US | disclosed |
| US-20100087466-A1 | NOVEL SMALL MOLECULE DNAK INHIBITORS | CHAPERONE TECHNOLOGIES, INC. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087466-A1 | NOVEL SMALL MOLECULE DNAK INHIBITORS | HSP90AB2P, HSPH1, HSP90AB1 | OPRK1 3373/4885OPRM1 4746/4885STAT3 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.